Stockreport

Adaptive Biotechnologies: Current Moat Is Strong, But Value Rides On Long-Term Innovation (Rating Upgrade) [Seeking Alpha]

Adaptive Biotechnologies Corporation  (ADPT) 
Last adaptive biotechnologies corporation earnings: 2/26 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: adhc.com
PDF Per my estimates, ADPT is priced for ~30% annual revenue growth and ~17% FCF margins, so the current valuation offers little margin of safety for investors. clonoSEQ' [Read more]